Amatangelo M et al. Iberdomide is immune stimulatory and induces deep anti-myeloma activity across doses in combination with daratumumab in patients with TNE NDMM from the CC-220-MM-001 study. EHA 2024;Abstract P847.
Arnulf B et al. Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D. ASCO 2024;Abstract 7505.
Bal S et al. BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Updated results from a phase 1 study. ASH 2023;Abstract 219.
Delforge M et al. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: Patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol 2024;11(3):e216-27. Abstract
Dhakal B et al. Phase 1 study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Results from at least 1-year follow-up in all patients. EHA 2024;Abstract S207.
Dhodapkar MV et al. Efficacy and safety of idecabtagene vicleucel (ide-cel) in patients with clinical high-risk newly diagnosed multiple myeloma (NDMM) with an inadequate response to frontline autologous stem cell transplantation (ASCT): KarMMa-2 cohort 2c extended follow-up. ASH 2023;Abstract 2101.
Dimopoulos MA et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med 2024;[Online ahead of print]. Abstract
Facon T et al. Final survival analysis of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: MAIA study. EHA 2024;Abstract P968.
Facon T et al. Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). ASCO 2024;Abstract 7500.
Garfall AL et al. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. ASCO 2024;Abstract 7540.
Gay F et al. Results of the phase III randomized Iskia trial: Isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. ASH 2023;Abstract 4.
Hilengrass J et al. The phase 2 CARTITUDE-2 trial: Updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1-3 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B). ASH 2023;Abstract 1021.
Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2024;[Online ahead of print]. Abstract
Jagannath S et al. Association of selinexor dose reductions with clinical outcomes in the BOSTON study. Clin Lymphoma Myeloma Leuk 2023;23(12):917-23.e3. Abstract
Leleu X et al. Idecabtagene vicleucel (ide-cel) in patients (pts) with clinical high-risk early relapse multiple myeloma (MM) without front-line (1L) autologous stem cell transplantation (ASCT): KarMMa-2 cohort 2b. EHA 2024;Abstract S208.
Leleu XP et al. Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus IsaRd in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI). ASCO 2024;Abstract 7501.
Lentzsch S et al. Linvoseltamab in patients with relapsed/refractory multiple myeloma in the LINKER-MM1 study: Depth and durability of response at 14-month median follow-up. EHA 2024;Abstract S212.
Lesokhin AM et al. Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results. Nat Med 2023;29(9):2259-67. Abstract
Madan S et al. Novel selinexor triplet and quadruplet regimens (SND, SPED, SBD, SDPD): Results from the phase 1b/2 STOMP multiple myeloma trial. EHA 2024;Abstract P999.
Martin T et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: Updated results from IKEMA, a randomized phase 3 study. Blood Cancer J 2023;13(1):72. Abstract
Mateos MV et al. Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial. Eur J Haematol 2024;113(2):242-52. Abstract
Nadeem O et al. Safety and preliminary efficacy of BMS-986393, a GPRC5D CAR T cell therapy, in patients with relapsed/refractory (RR) multiple myeloma (MM) and 1-3 prior regimens: First results from a phase 1 study. EHA 2024;Abstract P951.
Raab MS et al. Isatuximab, lenalidomide, bortezomib and dexamethasone for newly-diagnosed, transplant-eligible multiple myeloma: Post transplantation interim analysis of the randomized phase III GMMG-HD7 trial. EHA 2024;Abstract S202.
Rasche L et al. Long-term efficacy and safety results from the phase 1/2 MonumenTAL-1 study of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. EHA 2024;Abstract P915.
Richardson PG et al. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: Final overall survival analysis. Haematologica 2024;109(7):2239-49. Abstract
Richardson PG et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and daratumumab (DARA) or elotuzumab (ELO) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the CC-92480-MM-002 trial. ASH 2023;Abstract 1013.
Richardson PG et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med 2023;389(11):1009-22. Abstract
Rodriguez-Otero P et al. Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) with DARA-R maintenance in transplant-eligible patients with newly diagnosed multiple myeloma (NDMM): Minimal residual disease (MRD) analysis in the PERSEUS trial. ASCO 2024;Abstract 7502.
Rodríguez Otero P et al. Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3. ASH 2023;Abstract 1028.
San-Miguel J et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 2023;389(4):335-47. Abstract
Sonneveld P et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024;390(4):301-13. Abstract
Tomasson M et al. Long-term survival after elranatamab monotherapy in patients with relapsed or refractory multiple myeloma: MagnetisMM-3. EHA 2024;Abstract 932.
Weisel K et al. Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). EHA 2024;Abstract S211.